BPC 157: What Research Shows (and What It Doesn't) Meeting Point Health BPC 157 Dosing (Common Protocols), Oral Subcutaneous, 500 mcg daily, Duration: 6 weeks, Intramuscular Peritendinous, 1 mg daily, Duration: 6 weeks, Note:, Not approved by FDA or Frontiers Pharmacokinetics, distribution, metabolism, and excretion of body protective compound 157, a potential drug for treating various wounds, in rats and dogs How necessary is the local injection site when adminstering BPC157 , In the video, I break down exactly how to use it and why both local and systemic injection can have benefits, Watch carefully